The WACC of Recro Pharma Inc (REPH) is 11.5%.
| Range | Selected | |
| Cost of equity | 7.30% - 13.10% | 10.20% |
| Tax rate | 27.00% - 27.00% | 27.00% |
| Cost of debt | 14.20% - 20.60% | 17.40% |
| WACC | 8.9% - 14.1% | 11.5% |
| Category | Low | High |
| Long-term bond rate | 3.2% | 3.7% |
| Equity market risk premium | 4.2% | 5.2% |
| Adjusted beta | 0.99 | 1.7 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 7.30% | 13.10% |
| Tax rate | 27.00% | 27.00% |
| Debt/Equity ratio | 0.99 | 0.99 |
| Cost of debt | 14.20% | 20.60% |
| After-tax WACC | 8.9% | 14.1% |
| Selected WACC | 11.5% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for REPH:
cost_of_equity (10.20%) = risk_free_rate (3.45%) + equity_risk_premium (4.70%) * adjusted_beta (0.99) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.